{"id":"triple-combination-formula","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3659620","moleculeType":"Small molecule","molecularWeight":"456.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without specification of the exact three components, the mechanism cannot be precisely defined. Triple combination formulas typically work by targeting multiple pathways or mechanisms simultaneously to enhance efficacy. The Federal University of São Paulo has developed this marketed formulation, likely for a specific therapeutic indication.","oneSentence":"A triple combination formula that combines three active pharmaceutical ingredients to produce synergistic therapeutic effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:14:34.994Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT06425666","phase":"NA","title":"Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2025-01-24","conditions":"Cataract Surgery, Cataract and Fuchs Endothelial Corneal Dystrophy","enrollment":120},{"nctId":"NCT06761313","phase":"PHASE4","title":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-03-01","conditions":"Glaucoma, Quality of Life (QOL)","enrollment":40},{"nctId":"NCT06201624","phase":"PHASE1","title":"Oral Isotretinoin in Melasma a Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2023-03-01","conditions":"Melasma","enrollment":40},{"nctId":"NCT02978716","phase":"PHASE2","title":"Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2017-02-02","conditions":"Triple-Negative Breast Neoplasms, Breast Neoplasm, Breast Cancer","enrollment":102}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Maleate Timolol 0.5%, Brimonidine Tartarate 0.2%, Bimatoprost 0.03%","modified Kligman formula"],"phase":"marketed","status":"active","brandName":"Triple combination formula","genericName":"Triple combination formula","companyName":"Federal University of São Paulo","companyId":"federal-university-of-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}